Memantina Qualigen

Memantine Hydrochloride, the active ingredient in Memantina Qualigen, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adults. GNH USA supplies Memantina Qualigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable global distribution.

Memantina Qualigen is an NMDA receptor antagonist used in the management of Alzheimer’s disease, targeting the neurodegenerative pathway associated with cognitive decline.

Alzheimer’s disease (moderate to severe): modest improvement in cognition and global function. Cognitive decline: may slow the rate of deterioration in memory and thinking. Daily living activities: helps maintain independence in routine tasks for a longer period.

Common Side Effects: - Dizziness - Headache - Constipation - Fatigue

Serious or Rare Side Effects: - Seizures - Severe skin reactions such as Stevens‑Johnson syndrome - Hepatic dysfunction - Suicidal thoughts or behavior - Psychosis or severe agitation

Memantina Qualigen should be used with caution in the following situations: - Renal impairment: dose may need adjustment. - History of seizures: monitor for increased seizure activity. - Cardiovascular disease: use cautiously due to possible blood pressure effects. - Concomitant use of other NMDA antagonists: avoid additive neurotoxicity. - Pregnancy and breastfeeding: safety unknown; avoid unless clearly needed. - Store at below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Major Interactions (Avoid): - Amantadine: increased risk of central nervous system adverse effects. - Other NMDA antagonists: additive neurotoxicity. - High‑dose vitamin D supplements: may alter memantine plasma concentrations.

Moderate Interactions (Monitor Closely): - Acetylcholinesterase inhibitors (e.g., donepezil): possible reduction in therapeutic benefit. - Diuretics: may affect renal clearance of memantine. - CNS depressants (e.g., benzodiazepines): enhanced sedation or dizziness.